Annual inventory: top ten global M&A transactions in the biomedical field in 2021

In 2021, global M&A transactions in the biomedical field will basically return to the level before the epidemic
.

Pharmaceutical companies are actively seeking to expand in frontier fields such as CXO, digital medicine, gene therapy, precision medicine, and rare disease drugs

Table 1: Top 10 M&A transactions in the global biomedical field in 2021

Source: Flint Creations compiled according to public information

01.
Thermo Fisher's US$17.
4 billion acquisition of PPD

In December 2021, Thermo Fisher Scientific completed the acquisition of PPD, Inc.
at a price of US$17.
4 billion
.

PPD is a global leader in providing drug research and development services (CRO) for the biopharmaceutical and biotechnology industries

With the completion of this transaction, Thermo Fisher Scientific will further expand its value proposition in the fields of biotechnology and pharmaceuticals, and provide coverage in the field of clinical development from drug discovery, evaluation of safety, effectiveness and medical effects, to drug clinical trial management , And world-class services for the entire process of drug development and production
.

02.
Siemens acquired Varian for USD 16.
4 billion

In April 2021, Siemens completed the acquisition of Varian at a price of 16.
4 billion U.
S.
dollars
.

Varian is the world's largest X-ray digital imaging company and a major manufacturer of products such as linear accelerators and gamma knives

The acquisition will realize a strong alliance between the two parties in the fields of imaging diagnosis, in vitro diagnosis and interventional therapy, and further promote Siemens to create a unique and highly integrated combination of medical imaging, laboratory diagnosis, artificial intelligence and treatment products, and use artificial intelligence Auxiliary analysis technology, in-depth development and provision of data-based precision medical services, redefining cancer diagnosis, treatment services and post-treatment management
.

With Varian becoming a new business unit of Siemens Healthcare, it is estimated that from fiscal year 2025, at least 300 million euros of synergy will be realized each year

03.
Baxter acquired Hillrom for US$12.
5 billion

In December 2021, Baxter paid US$156.
00 in cash for each Hillrom common stock at a purchase price of US$10.
5 billion and assumed Hillrom’s outstanding debt.
The total enterprise value of the transaction was approximately US$12.
5 billion
.

Baxter International was established in the United States in 1931 and is one of the leading companies in the global medical industry

Founded in 1915, Hillrom is the world's leading provider of patient care products and services.
Products and services include patient care beds, stretchers, patient monitors, operating tables, electrocardiographs, workflow systems, bedside medical equipment belt systems, etc.

.

The acquisition will promote Hill-Rom's networked care and patient monitoring to complement the combination of Baxter's hospital care products

04.
Merck acquired Acceleron Pharma for USD 11.
5 billion

In November 2021, Merck completed the acquisition of Acceleron with a cash of US$180 per share, with a total equity value of approximately US$11.
5 billion
.

Acceleron is a clinical-stage biopharmaceutical company focusing on the research and development of anticancer drugs and rare drugs for rare diseases.
The company's main drug candidate Sotatercept has an innovative mechanism of action and has the potential to improve the condition of patients with pulmonary arterial hypertension (PAH)
.

In addition, the U.

05.
Danaher acquires Aldevron for USD 9.
6 billion

In August 2021, Danaher completed the acquisition of Aldevron for US$9.
6 billion
.

Aldevron will operate as an independent operating company, and its brand will join the Danaher Life Science platform
.

Aldevron was founded in 1998 and is headquartered in Fargo, North Dakota, USA.

06.
Illumina acquires Grail for USD 8 billion

In August 2021, gene sequencing giant Illumina announced the completion of the acquisition of blood testing company Grail for US$8 billion, officially entering the early cancer screening market
.
Grail owns Galleri, a blood testing technology platform, which is based on Illumina's Next Generation Gene Sequencing (NGS) technology and can detect more than 50 types of cancer
.

After acquiring Graol, Illumina will become a tumor testing supplier
.
Illumina plans to expand its business to blood-based cancer diagnosis, detection and cancer patient prognosis in the future.
By 2035, the NGS tumor screening market will grow to 75 billion U.
S.
dollars
.

07.
Jazz Pharmaceuticals acquired GW Pharmaceuticals for USD 7.
2 billion

In February 2021, Jazz Pharmaceuticals acquired GW Pharmaceuticals for US$7.
2 billion
.
The transaction allows Jazz to enter the epilepsy market and expand its current products beyond the areas of sleep disorders and cancer
.
At the core of the deal is Epidiolex, which is approved to treat seizures in Lennox-Gastaut syndrome, tuberous sclerosis syndrome, or Dravet syndrome
.

Epidiolex is also the first cannabis-derived drug approved by the FDA and has been approved by the European Medicines Agency EMA under the name Epidiolex
.
GW also has a pipeline of cannabinoid products for the treatment of autism and schizophrenia, as well as a late-stage drug candidate nabiximols, called Sativex outside the United States, for the treatment of spasms in multiple sclerosis
.
Jazz estimates that about half of its revenue in 2022 will come from four new drugs, including Jazz’s sleepiness drug Sunosi, small cell lung cancer drug Zepzelca, Xyrem’s sister drug Xywav, and blood cancer drug JZP-458
.

08.
PerkinElmer acquired BioLegend for USD 5.
25 billion

In July 2021, PerkinElmer acquired BioLegend, a manufacturer of life science antibodies and reagents, for approximately US$5.
25 billion in cash and stock
.
After BioLegend joins in with its stem cell, oncology, genomics and other technologies, PerkinElmer's existing life science business will also expand into new areas
.
At the same time, BioLegend’s campus in San Diego, California will become PerkinElmer’s Global Center of Excellence (CoE) to develop research reagent products for the combined company
.

PerkinElmercheng's fields include diagnostics, life sciences, food and application markets, and its products cover the equipment, software, reagents and training services required for medical analysis and testing
.
Moreover, the pace of its expansion is still advancing rapidly, and the large-scale acquisitions in the past two years have covered multiple directions such as gene therapy and immunodiagnosis
.
San Diego-based BioLegend provides antibodies and reagents for scientific research and biopharmaceutical customers for cell counting, multiplex detection, protein genomics, magnetic cell separation, and bioprocessing
.
Among them, TotalSeq antibody can combine next-generation sequencing and single-cell labeling technology, which is favored by researchers
.

09.
Sanofi acquired Translate Bio for USD 3.
2 billion

On August 3, 2021, Sanofi announced that it will acquire Translate Bio, an mRNA vaccine development company, for US$3.
2 billion to accelerate the deployment of mRNA.
The goal is to focus on other strategic areas beyond vaccines, such as immunology, oncology, and The field of rare diseases releases the potential of mRNA vaccines
.

Translate Bio is a clinical-stage mRNA therapy company dedicated to the development of a new class of potentially transformative drugs for the treatment of diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity
.
Sanofi and Translate Bio are jointly committed to innovation in the mRNA field
.
With Sanofi's long-term expertise in developing and commercializing vaccines and other innovative drugs on a global scale, Translate Bio's mRNA technology can reach more people better and faster
.

10.
Horizon Therapeutics acquired Viela Bio for US$3.
05 billion

On February 1, 2021, Horizon Therapeutics announced the acquisition of Viela Bio for approximately US$3.
05 billion.
Horizon will harvest Viela Bio’s approved anti-CD19 monoclonal antibody Uplizna (inebilizumab-cdon) for the treatment of neuromyelitis optica Lineage disease (NMOSD), a variety of research therapies in the research and development pipeline, and Viela Bio's scientific expertise in autoimmune diseases and deep experience in biological product development
.

The acquisition will advance Horizon's transformation into an innovation-driven biotechnology company.
Horizon plans to maximize the full potential of the Viela pipeline, including the pursuit of more indications in the future
.
Viela Bio is committed to the development of precision therapies for the treatment of autoimmune diseases.
The research and development direction is mainly focused on 3 biological pathways related to various autoimmune diseases, namely autoantibody pathway, CD40/CD40L costimulatory pathway, and innate immunity Access
.

Failure case: Anhong Capital and Aurora failed to acquire Sobi for US$8.
1 billion

In September 2021, global private equity giant Advent International and GIC related company Aurora announced that they would acquire Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) for US$8.
1 billion
.
Sobi is a Stockholm-based biopharmaceutical company that specializes in the development of rare disease treatments
.
That month, Sobi's share price soared due to the takeover offer, and the Nasdaq in Stockholm rose by 26%
.

In December 2021, Anhong Capital and Aurora’s acquisition plan for Sobi was blocked by the British pharmaceutical company AstraZeneca on the grounds of withholding 8% of its shares.
The failure of the transaction directly caused Sobi’s share price to plummet by nearly 25%
.